226 related articles for article (PubMed ID: 30112806)
1. Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination.
Chapple AG; Thall PF
Pharm Stat; 2018 Nov; 17(6):734-749. PubMed ID: 30112806
[TBL] [Abstract][Full Text] [Related]
2. Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.
McGovern A; Chapple AG; Ma C
Pharm Stat; 2022 Nov; 21(6):1138-1148. PubMed ID: 35560864
[TBL] [Abstract][Full Text] [Related]
3. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
[TBL] [Abstract][Full Text] [Related]
4. Subgroup-specific dose finding for phase I-II trials using Bayesian clustering.
Curtis A; Smith B; Chapple AG
Stat Med; 2022 Jul; 41(16):3164-3179. PubMed ID: 35429178
[TBL] [Abstract][Full Text] [Related]
5. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
North B; Kocher HM; Sasieni P
BMC Cancer; 2019 Jun; 19(1):632. PubMed ID: 31242873
[TBL] [Abstract][Full Text] [Related]
6. A simulation study of methods for selecting subgroup-specific doses in phase 1 trials.
Morita S; Thall PF; Takeda K
Pharm Stat; 2017 Mar; 16(2):143-156. PubMed ID: 28111916
[TBL] [Abstract][Full Text] [Related]
7. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
8. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
Polley MY
Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
[TBL] [Abstract][Full Text] [Related]
9. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
Yuan Y; Lin R; Li D; Nie L; Warren KE
Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
[TBL] [Abstract][Full Text] [Related]
10. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
11. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
12. Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment.
Andrillon A; Biard L; Lee SM
J Biopharm Stat; 2023 Jul; ():1-12. PubMed ID: 37496233
[TBL] [Abstract][Full Text] [Related]
13. Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects.
Yin Z; Mander AP; de Bono JS; Zheng H; Yap C
JCO Precis Oncol; 2024 Jan; 8():e2300441. PubMed ID: 38181316
[TBL] [Abstract][Full Text] [Related]
14. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.
Zhou Y; Lin R; Lee JJ; Li D; Wang L; Li R; Yuan Y
Stat Med; 2022 May; 41(11):1918-1931. PubMed ID: 35098585
[TBL] [Abstract][Full Text] [Related]
15. Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM.
Braun TM; Levine JE; Ferrara JL
Control Clin Trials; 2003 Dec; 24(6):669-81. PubMed ID: 14662273
[TBL] [Abstract][Full Text] [Related]
16. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
[TBL] [Abstract][Full Text] [Related]
17. Monitoring late-onset toxicities in phase I trials using predicted risks.
Bekele BN; Ji Y; Shen Y; Thall PF
Biostatistics; 2008 Jul; 9(3):442-57. PubMed ID: 18084008
[TBL] [Abstract][Full Text] [Related]
18. Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups.
Lee J; Thall PF; Msaouel P
Stat Med; 2021 Oct; 40(24):5199-5217. PubMed ID: 34636054
[TBL] [Abstract][Full Text] [Related]
19. Using the time-to-event continual reassessment method in the presence of partial orders.
Wages NA; Conaway MR; O'Quigley J
Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
[TBL] [Abstract][Full Text] [Related]
20. How to design a dose-finding study using the continual reassessment method.
Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]